Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Increases By 213.1%

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 61,344 shares, a growth of 213.1% from the January 15th total of 19,594 shares. Approximately 9.0% of the company’s shares are short sold. Based on an average trading volume of 506,631 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 506,631 shares, the days-to-cover ratio is presently 0.1 days. Approximately 9.0% of the company’s shares are short sold.

Analysts Set New Price Targets

BDRX has been the subject of several research analyst reports. Wall Street Zen raised shares of Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

BDRX stock opened at $1.21 on Thursday. Biodexa Pharmaceuticals has a twelve month low of $1.20 and a twelve month high of $53.00. The stock’s 50 day moving average is $2.94 and its 200-day moving average is $5.17.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.